NTLA
Intellia Therapeutics Inc
NASDAQ · Biotechnology
$12.28
+1.19 (+10.73%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 67.82M | 56.27M | 245.97M | 223.20M | 196.34M |
| Net Income | -608,176,655 | -454,126,764 | -43,287,376 | -30,251,127 | -26,608,774 |
| EPS | — | — | — | — | — |
| Profit Margin | -896.8% | -851.9% | -17.6% | -13.6% | -13.6% |
| Rev Growth | +20.5% | +20.5% | +17.8% | +19.1% | +20.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 0 | 0 | 705.77M | 735.97M | 562.69M |
| Total Equity | — | — | 1.04B | 1.00B | 1.02B |
| D/E Ratio | — | — | 0.68 | 0.73 | 0.55 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -613,991,318 | -483,939,062 | -55,131,039 | -52,265,042 | -37,903,322 |
| Free Cash Flow | — | — | -42,116,040 | -47,461,783 | -26,029,407 |